Current Press Releases
In some elderly patients, levothyroxine may be linked with increased mortality
March 19, 2018
|Contact: Jenni Glenn Gingery
Associate Director, Communications and Media Relations
|Contact: Colleen Williams
Manager, Public Relations
Chicago, IL - Treating some elderly people with levothyroxine may put them at increased risk of death, new research from Israel reports. The results will be presented on Tuesday, March 20, at ENDO 2018, the 100th annual meeting of the Endocrine Society in Chicago, Ill.
"In patients who are 65 years of age or above with subclinical hypothyroidism and thyroid-stimulating hormone (TSH) <10 mIU/L (milli-international units per liter), treatment with levothyroxine is associated with significantly increased mortality," said lead study author Joseph Meyerovitch, M.D., professor and senior physician at the Jesse and Sara Lea Shafer Institute for Endocrinology and Diabetes of the Schneider Children's Medical Center of Israel in Petah Tikva, and Chief Pediatrician Medicine Wings, Community Division, Clalit Health Services, Tel Aviv, Israel
"Subclinical hypothyroidism, the situation when thyroid function is not normal but is not defined as a disease, is very common," he added. "Physicians should consider the results of the study before they begin treatment with levothyroxine in individuals 65 years of age and above who have subclinical hypothyroidism and TSH values under 10 mIU/L."
Meyerovitch and colleagues determined which patients 65 years or older with TSH levels between 4.2 and 10 mIU/L died during the years 2012 through 2016 (cases) and matched them with individuals who did not die during that period (controls).
The authors matched the patients according to age, gender, Charlson comorbidity index, TSH testing date, follow-up duration, and TSH quartile, and they compared the use of levothyroxine between the groups. They excluded all patients with known thyroid disease and those who had received anti-thyroid medications or glucocorticoids in the year before they were tested for TSH.
During the follow-up period, 419 people who died were matched with 1,558 people who did not die. Treatment with levothyroxine was linked with significantly increased mortality (hazard ratio = 1.19).
Factors associated with death included age, senile dementia, congestive heart failure, cerebrovascular disease, and chronic renal failure. Femoral fractures and atrial fibrillation after beginning to take levothyroxine were not more prevalent in individuals who died during follow-up.
Endocrinologists are at the core of solving the most pressing health problems of our time, from diabetes and obesity to infertility, bone health, and hormone-related cancers. The Endocrine Society is the world’s oldest and largest organization of scientists devoted to hormone research and physicians who care for people with hormone-related conditions.
The Society has more than 18,000 members, including scientists, physicians, educators, nurses and students in 122 countries. To learn more about the Society and the field of endocrinology, visit our site at www.endocrine.org. Follow us on Twitter at @TheEndoSociety and @EndoMedia.